Thoratec Reports 14 Percent Growth in Cardiovascular Division Sales as Third Quarter Revenues Increase Ni...(xpense): Interest expense ...),Health

Date:11/4/2009

xpense): Interest expense (3,261) (2,834) (9,167) (8,249) Interest income and other 7,134 2,183 9,759 6,642 ----- ----- ----- ----- Income before income taxes 17,461 7,536 27,720 16,797 Income tax expense (5,684) (1,478) (8,483) (3,793) ------ ------ ------ ------ Net income $11,777 $6,058 $19,237 $13,004 ======= ====== ======= ======= Net income per share Basic $0.21 $0.11 $0.34 $0.24 ===== ===== ===== ===== Diluted $0.20 $0.11 $0.33 $0.23 ===== ===== ===== ===== Shares used to compute net income per share: Basic 56,683 55,328 56,511 54,702 Diluted 58,006 56,703 57,859 55,689 (1) Adjusted for the retrospective adoption of the accounting for convertible debt instruments that may be settled in cash upon conversion, including partial settlements in accordance with Financial Accounting Standards Board ("FASB") issued Accounting Standards Codification ("ASC") 470-20, Debt. The following table reconciles the specific items excluded from GAAP net income in the calculation of non-GAAP net income for the periods shown below: THORATEC CORPORATION Reconciliation of GAAP to Non-GAAP Net Income (Unaudited) (in thousands, except for per share data) Three Months Ended Nine Months Ended -----------------
'/>"/>

SOURCE Thoratec Corporation Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19
Related medicine technology :

1. Thoratec Announces FDA Approval of HeartMate II(R) for Bridge-To-Transplantation
2. Thoratec Says Interim Data Analysis Demonstrates Statistical Superiority for the HeartMate II(R) in Destination Therapy Trial
3. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
4. Spherix Reports Second Quarter Earnings
5. Tapestry Reports Second Quarter 2007 Results
6. Callisto Reports on Second-Quarter 2007 Milestones
7. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
8. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
9. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
10. TAXUS WOMAN Study Reports Positive Clinical Outcomes for the TAXUS(R) Drug-eluting Stent in Women
11. Biopure Reports on Meeting with the FDA